* Precision BioSciences Inc DTIL.OQ reported a quarterly
adjusted loss of 35 cents per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of $-6.90. The mean expectation of six analysts
for the quarter was for a loss of $1.91 per share. Wall Street
expected results to range from $-2.60 to -45 cents per share.
* Revenue rose 100.3% to $17.58 million from a year ago;
analysts
expected $6.02 million.
* Precision BioSciences Inc's reported EPS for the quarter
was
$1.70.
* The company reported quarterly net income of $8.59
million.
* Precision BioSciences Inc shares had fallen by 21.5% this
quarter and lost 2.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 25% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Precision
BioSciences Inc is $30.00
This summary was machine generated from LSEG data May 13 at
01:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.91 -0.35 Beat
Dec. 31 2023 -2.05 -4.06 Missed
Sep. 30 2023 -4.87 -2.10 Beat
Jun. 30 2023 -7.32 -3.00 Beat